Overview of Larimar Therapeutics Developments
Larimar Therapeutics Inc. (NASDAQ: LRMR) has recently seen its stock taking a dip after some patients in a pivotal study reported allergic reactions. This comes in the backdrop of their long-term open-label (OL) study, where participants have been using daily subcutaneous injections of nomlabofusp to treat a condition known as Friedreich’s ataxia (FA).
The Open-Label Study
This ongoing OL study is crucial as it evaluates various factors such as safety, tolerability, pharmacokinetics (PK), as well as the levels of the FXN protein in skin and buccal cells. It also examines exploratory pharmacodynamic (PD) markers, which include lipid profiles and various clinical outcomes over time.
Participants and Dosing Adjustments
Initially, patients were given a daily dose of 25 mg of nomlabofusp, but this was adjusted to 50 mg starting in what was initially planned for late 2024. New patients have been receiving this higher dosage since.
Reported Reactions and Response
Recent reports highlight that out of 65 patients who have received at least one dose, there were seven cases of anaphylaxis leading to withdrawals from the study. Notably, these incidents primarily occurred within the first six weeks of treatment.
New Safety Protocols
To address these concerns, Larimar has revised its protocol. The updated approach will start with a test dose of 5 mg, followed by a 25 mg dose administered an hour later under observation. After this, a consistent daily administration of 25 mg for 30 days will occur before transitioning to 50 mg once daily.
Patient Enrollment and Future Plans
The company is eager to include younger patients, specifically those aged 2-11 years, into the OL study. This strategic move could open new avenues for the treatment of FA in childhood.
Other Discontinuations and Improvement Trends
It's worth noting that aside from anaphylaxis, there were instances of generalized urticaria, seizures, and other non-treatment related discontinuations. Nevertheless, positive trends were observed in various clinical assessments like the modified Friedreich Ataxia Rating Scale (mFARS) and other performance metrics over the year.
Outlook on Approvals
Looking ahead, Larimar’s submission for potential accelerated approval for nomlabofusp in treating FA is anticipated to remain on schedule for the second quarter of 2026. This could significantly impact their journey and the stock’s performance.
Market Response
As of the latest trading update, LRMR stock has noted a decline of approximately 23.75%, currently priced at $3.89. Such fluctuations are common in the biotech sector, especially following significant clinical study revelations.
Frequently Asked Questions
What is the main condition Larimar Therapeutics is targeting?
Larimar Therapeutics is focusing on treating Friedreich’s ataxia (FA) through their clinical study using nomlabofusp.
What recent issues did participants in the study experience?
Participants experienced allergic reactions, including seven cases of anaphylaxis that led to withdrawals from the study.
What changes has Larimar made to their dosing regimen?
The dosing regimen now starts with a 5 mg test dose followed by a 25 mg dose, administered under observation before increasing to 50 mg.
When is the company planning to submit for accelerated approval?
Larimar intends to submit for accelerated approval for nomlabofusp in the second quarter of 2026.
How has the stock price reacted to recent news?
LRMR stock has dropped by about 23.75%, currently trading around $3.89.
